Verapamil Ameliorates Hepatic Metaflammation by Inhibiting Thioredoxin-Interacting Protein/NLRP3 Pathways
Authors:
Open Access
- 31 October 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 640
Abstract
Activation of thioredoxin-interacting protein (TXNIP)/nod-like receptor protein 3 (NLRP3) inflammasome plays a critical role in pathogenesis of non-alcoholic fatty liver disease. This study investigated the protective effects of verapamil on hepatic metaflammation in a rodent model of high-fat (HF) diet-induced obesity (DIO). DIO was induced in a subset of mice provided with HF diet (45% kcal fat). After 10 weeks of HF diet, verapamil was administered by intraperitoneal injection. The experimental groups included the following: (1) normal diet group, (2) normal diet + treatment with verapamil (VER) group, (3) HF control group, (4) HF+VER (25 mg/kg/day) group. After 1 week of each treatment, blood and liver tissues were collected, and glucose control, serum triglyceride (TG) level, inflammation, and TXNIP/NLRP3 inflammasome were analyzed. Verapamil administration caused no alteration in food intake. HF diet impaired glucose control and increased body weight and serum TG levels. Hepatic inflammation was aggravated in HF-fed mice, as demonstrated by increased levels of pro-inflammatory markers interleukin-1β (IL-1β) and IL-18 in the liver. On the other hand, verapamil administration significantly improved glucose control, body weight, and serum TG levels. Verapamil treatment also reduced pro-inflammatory marker levels. These improvements were accompanied by alterations in activation of TXNIP/NLRP3 inflammasome. The observed results demonstrate that verapamil ameliorates hepatic metaflammation by inhibiting TXNIP/NLRP3 pathways.Keywords
Funding Information
- National Natural Science Foundation of China (81571946)
This publication has 39 references indexed in Scilit:
- Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitisHepatology, 2016
- Inflammasomes in non-alcoholic fatty liver diseaseFrontiers in Bioscience-Landmark, 2016
- Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and InflammationInternational Journal of Molecular Sciences, 2014
- Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activationMetabolism, 2014
- Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistanceJournal of Endocrinology, 2013
- Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathwaysEuropean Journal of Nutrition, 2013
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- Current therapeutic strategies in non‐alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism, 2011
- The InflammasomesCell, 2010
- The NLRP3 Inflammasome: A Sensor for Metabolic Danger?Science, 2010